Peripheral benzodiazepine receptor messenger rna is decreased in lymphocytes of generalized anxiety disorder patients

Biological Psychiatry

Volumn 43, Issue 10, 1998, Pages 767-773

  Rocca, Paola ^a   Beoni, Anna Maria ^a   Eva, Carola ^a   Ferrero, Patrizia ^a   Zanalda, Enrico ^a   Ravizza, Luigi ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Benzodiazepines; Generalized anxiety disorder; Peripheral benzodiazepine receptor; Peripheral benzodiazepine receptor messenger RNA

Indexed keywords

BENZODIAZEPINE RECEPTOR; BETA ACTIN; DELORAZEPAM; MESSENGER RNA; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; TRITIUM;

ADULT; ANXIETY NEUROSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LIGAND BINDING; MALE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; RECEPTOR BINDING;

EID: 0032524047     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(97)00279-5     Document Type: Article

References (41)

1. Alho H, Varga V, Krueger KE (1994): Expression of mitochondrial benzodiazepine receptor and its putative endogenous ligand diazepam binding inhibitor in cultured primary astrocytes and C-6 cells: Relation to cell growth. Cell Growth Differ 5:1005-1014.
2. Anholt RRH, Pedersen PL, De Souza EB, Snyder SH (1986): The peripheral-type benzodiazepine receptor: Localization to the mitochondrial outer membrane. J Biol Chem 261:576-583.
3. Ansseau M, von Frenckell R, Cerfontaine JL, Papart P (1991): Pilot study of PK 11195, a selective ligand for the peripheral-type benzodiazepine binding sites, in inpatients with anxious or depressive symptomatology. Pharmacopsychiatry 24:8-12.
4. Auta J, Romeo E, Kozikowski A, Ma D, Costa E, Guidotti A (1993): Participation of mitochondiral diazepam binding inhibitor receptors in the anticonflict, antineophobic and anticonvulsant action of 2-aryl-3-indoleacetamide and imidazopyridine derivatives. J Pharmacol Exp Ther 265:649-656.
5. Benavides JJ, Guilloux F, Allam DE, Uzan A, Mizoule J, Renault C, et al (1984): Opposite effects of an agonist, Ro 5-4864, and an antagonist, PK 11195, of the peripheral-type benzodiazepine binding sites on audiogenic seizures in DBA/2J mice. Life Sci 34:2613-2620.
6. 3H)-diazepam binding. Proc Natl Acad Sci USA 74:3805-3809.
7. Cleveland DW, Lopata MA, MacDonald RJ, Cowan NJ, Rutter WJ, Kirschner MW (1980): Number and evolutionary conservation of α-and β-tubulin and cytoplasmic β-and γ-actin genes using specific cloned cDNA probes. Cell 20:95-105.
8. Drugan RC (1996): Peripheral benzodiazepine receptors: Molecular pharmacology to possible physiological significance in stress-induced hypertension. Clin Neuropharmacol 19:475-496.
9. Drugan RC, Holmes PV (1991): Central and peripheral benzodiazepine receptors: Involvement in an organism's response to physical and psychological stress. Neurosci Biobehav Rev 15:277-298.
10. 3H)Ro 5-4864 binding to peripheral benzodiazepine receptors in rat heart and kidney. Pharmacol Biochem Behav 30:1015-1020.
11. 3H)Ro 5-4864 binding in rat kidney. Brain Res 535:151-154.
12. Eva C, Fusco M, Bono C, Tria MA, Ricci Galamero S, Leon A, et al (1992): Nerve growth factor modulates the expression of muscarinic cholinergic receptor messenger RNA in telencephalic neuronal cultures from newborn rat brain. Mol Brain Res 14:344-351.
13. Ferrarese C, Appollonio I, Frigo M, Perego M, Riolti R, Trabucchi M, et al (1990): Decreased density of benzodiazepine receptors in lymphocytes of anxious patients: Reversal after chronic diazepam treatment. Acta Psychiatr Scand 82:169-173.
14. Ferrarese C, Mennini T, Pecora N, Pierpaoli C, Frigo M, Marzorati C, et al (1991): Diazepam binding inhibitor (DBI) increases after acute stress in rat. Neuropharmacology 30: 1445-1452.
15. Ferrero P, Benna P, Costa P, Tarenzi L, Baggio G, Bergamasco B, et al (1988): Diazepam binding inhibitor like immunoreactivity (DBI-LI) in human CSF: Correlation with neurological disorders. J Neurol Sci 87:327-349.
16. 3H-PK 11195 binding to "peripheral-type" benzodiazepine receptors on human lymphocytes. Evidence of decreased binding in hepatic encephalopathy. J Neurol Sci 102:209-219.
17. Gavish M, Bar-Ami S, Weizman R (1992a): The endocrine system and mitochondrial benzodiazepine receptors. Mol Cell Endocrinol 88:1-13.
18. Gavish M, Katz Y, Bar-Ami S, Weizman R (1992b): Biochemical, physiological, and pathological aspects of the peripheral benzodiazepine receptor. J Neurochem 58:1589-1601.
19. Gavish M, Laor N, Bidder M, Fisher D, Fonia O, Muller U, et al (1996): Altered platelet peripheral-type benzodiazepine receptor in posttraumatic stress disorder. Neuropsychopharmacology 14:181-186.
20. Guarneri P, Papadopoulos V, Pan B, Costa E (1992): Regulation of pregnenolone synthesis in C6-2B glioma cells by 4′-chlordiazepam. Proc Natl Acad Sci USA 89:5118-5122.
21. Kalogeras KT, Calogero AE, Kuribayiashi T, Khan I, Gallucci WT, Kling MA, et al (1990): In vitro and in vivo effects of the triazolobenzodiazepine alprazolam on hypothalarnic-pituitary-adrenal function: Pharmacological and clinical implications. J Clin Endocrinol Metab 70:1462-1471.
22. Krueger KE, Papadopoulos V (1992): Mitochondrial benzodiazepine receptors and the regulation of steroid biosynthesis. Annu Rev Pharmacol Toxicol 32:211-237.
23. Langer SZ, Arbilla S, Tan S, Lloyd KG, George P, Allen J, et al (1990): Selectivity for omega-receptor subtypes as a strategy for the development of anxiolytic drugs. Pharmacopsychiatry 23:103-107.
24. Le Fur G, Perrier ML, Vaucher N, Imbault F, Flamier H, Benavides J, et al (1983): Peripheral benzodiazepine binding sites: Effect of PK 11195, 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide. Life Sci 32: 1839-1847.
25. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ (1951): Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
26. Marazziti D, Rotondo A, Martini C, Giannacini G, Lucacchini A, Pancioli-Guadagnucci ML, et al (1994): Changes in peripheral benzodiazepine receptors in patients with panic disorder and obsessive-compulsive disorder. Neuropsychobiology 29: 8-11.
27. McEwen BS (1991): Non-genomic and genomic effects of steroids on neural activity. Trends Pharmacol Sci 12:141-147.
28. Mizoule J, Gauthier A, Uzan A, Renault C, Dubroeucq MC, Gueremy C, et al (1985): Opposite effects of two ligands for peripheral-type benzodiazepine binding sites, PK 11195 and Ro 5-4864, in a conflict situation in the rat. Life Sci 36:1059-1068.
29. Papadopoulos V (1993): Peripheral-type benzodiazepine/diazepam binding inhibitor receptor: Biological role in steroidogenic cell function. Endocr Rev 14:222-240.
30. Parola AL, Stump DG, Pepperl DJ, Krueger KE, Regan JW, Laird HE II (1991): Cloning and expression of a pharmacologically unique bovine peripheral-type benzodiazepine receptor isoquinoline binding protein. J Biol Chem 266:14082-14087.
31. A receptors. Neuron 4:759-765.
32. Rickeis K, Schweizer E, Csanalosi I, Case G, Chung H (1988): Long-term treatment of anxiety and risk of withdrawal. Arch Gen Psychiatry 45:444-450.
33. Riond J, Mattei MG, Kaghad M, Dumont X, Guillemot JC, Le Fur G, et al (1991): Molecular cloning and chromosomal localization of a human peripheral-type benzodiazepine receptor. Eur J Biochem 195:305-311.
34. Rocca P, Ferrero P, Gualerzi A, Zanalda E, Maina G, Bergamasco B, et al (1991): Peripheral-type benzodiazepine receptors in anxiety disorders. Acta Psychiatr Scand 84:537-544.
35. Rocca P, Bellone G, Benna P, Bergamasco B, Ravizza L, Ferrero P (1993): Peripheral-type benzodiazepine receptors and diazepam binding inhibitor-like immunoreactivity distribution in human peripheral blood mononuclear cells. Immunopharmacology 25:163-178.
36. Sprengel R, Werner P, Seeburg PH, Mukhin AG, Santi MR, Grayson DR, et al (1989): Molecular cloning and expression of cDNA encoding a peripheral-type benzodiazepine receptor. J Biol Chem 264:20414-20421.
37. Tallman JF, Paul SM, Skolnick P, Gallager DW (1980): Receptors for the age of anxiety: Pharmacology of benzodiazepines. Science 207:274-281.
38. Verma A, Snyder SH (1989): Peripheral type benzodiazepine receptors. Annu Rev Pharmacol Toxicol 29:307-322.
39. Wang JKT, Taniguchi T, Spector S (1984): Structural requirements for the binding sites of benzodiazepines to their peripheral-type sites. Mol Pharmacol 25:349-351.
40. Weizman R, Tanne Z, Granek M, Karp L, Golomb M, Tyano S, et al (1987): Peripheral benzodiazepine binding sites on platelet membranes are increased during diazepam treatment of anxious patients. Eur J Pharmacol 138:289-292.
41. Weizman R, Hermesh H, Karp L, Dar DE, Munitz H, Gavish M (1993): The platelet benzodiazepine receptor is unaltered in obsessive-compulsive disorder. Clin Neuropharmacol 16: 211-215.